Appointments

866.320.4573

Request an Appointment

Questions

800.223.2273

Contact us with Questions

Expand Content

Stanley Hazen, MD, PhD

216.445.9763

Stanley Hazen, MD, PhD
Department: Cellular and Molecular Medicine
Department Chair
Location: Cleveland Clinic Main Campus
Mail Code NC10
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.445.9763
WorkFax:216.444.9404
Stanley Hazen, MD, PhD
Department: Cardiovascular Medicine
Section Head
Location: Cleveland Clinic Main Campus
Mail Code NC10
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.445.9763
WorkFax:216.444.8856
Stanley Hazen, MD, PhD
Department: Lerner Research Institute
Vice Chair for Translational Research
Location: Cleveland Clinic Main Campus
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.445.9763
WorkFax:216.444.9404
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

Stanley Hazen, MD, PhD, is the Head of the Section for Preventive Cardiology and Rehabilitation, Vice Chair of Translational Research, Lerner Research Institute, Director for the Center for Cardiovascular Diagnostics and Prevention, Director of the Cleveland Clinic Mass Spectrometry Core Facilities, Department Chair in the Department of Cell Biology and Section Head in the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic.

Dr. Hazen is board-certified as a Diplomat of the American Board of Internal Medicine. He has also completed subspecialty training in endocrinology, diabetes and metabolism. He sees patients within the Preventive Cardiology Clinic, specializing in preventive cardiovascular medicine care of patients including treatment of hyperlipidemia, diabetes, hypertension, obesity. He also sees patients within the Cardiovascular Rehabilitation program. His research interests include understanding the role of inflammation and oxidant stress in the pathogenesis of atherosclerosis and other inflammatory diseases. He is an expert in mechanisms of atherosclerosis, HDL structure and metabolism, the biochemistry of leukocyte peroxidases, free radicals and reactive oxygen species and mechanisms of oxidative damage.

Dr. Hazen has published over 200 peer-reviewed articles, invited reviews and book chapters in the fields of atherosclerosis, oxidation and inflammation chemistry, and cardiovascular disease. He has received many honors and awards for his research work, which has contributed to new understandings of inflammation in cardiovascular disease and the development of new diagnostic and treatment tools. He is listed as a co-inventor on multiple patents for his work in identifying patients at increased risk for cardiovascular disease, diagnosing asthma, and treating inflammation and associated complications. He has been principal investigator on numerous National Institutes of Health grants and research awards related to his specialty interests.

He serves as reviewer for more than 20 scientific journals including Circulation, Analytical Biochemistry, Journal of Clinical Investigation, Journal of Biological Chemistry and the Journal of Lipid Research. Dr. Hazen is Associate Editor of the Journal of Lipid Research, and serves on the editorial board of Circulation, The Journal of Biological Chemistry and Free Radicals in Biology & Medicine. He has been invited to lecture at national and international symposia and conferences in both basic science and clinical fields alike, as well as workshops held by the National Academy of Science, and National Heart, Lung and Blood Institutes (National Institutes of Health) on Emerging Science for Environmental Health Decisions, mechanisms of atherogenesis, pulmonary immunobiology and inflammation, the origins of asthma, and nitric oxide biology.

Dr. Hazen has received numerous awards including election to membership in honorary societies in science and clinical arenas alike including the American Society for Clinical Investigation (ASCI) and the American Association of Physicians (AAP). He also is an elected fellow of the American Association for the Advancement of Science (AAAS). He holds memberships to the American College of Physicians, the American Federation for Medical Research, the American Heart Association Scientific Council for Arteriosclerosis, the American Medical Association, the American Society for Mass Spectrometry, the International Society for Free Radical Research, the Society for Free Radical Biology & Medicine, and the American Society for Investigative Pathology.

Professional Highlights

  • Chair, Gordon Research Conference on Oxygen Radicals
  • Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular Biology Award for Basic Science and Clinical Research
  • Election, Association of American Physicians (AAP)
  • Election, Fellow of American Heart Association Scientific Council for Arteriosclerosis
  • Election, American Society for Clinical Investigation

Education & Fellowships

Fellowship - Barnes-Jewish Hospital
Endocrinology
St. Louis, MO USA
1996
Residency - Barnes-Jewish Hospital
Internal Medicine
St. Louis, MO USA
1994
Doctorate - Washington University
St. Louis, MO USA
1992
Medical School - Washington University School of Medicine
St. Louis, MO USA
1992
Undergraduate - Washington University
St. Louis, MO USA
1985

Specialty Interests

Cardiovascular risk evaluation, coronary artery disease, high cholesterol, cardiovascular disease, cardiac rehabilitation, C-reactive protein testing, preventive cardiology

Awards & Honors

  • Howard Hughes Medical Institute Research Fellowship for Physicians Award, 1995-1997 
  • AAP, ASCI, and AFMR Certificate of Achievement Award, 1997 
  • Marilyn Hansen American Thoracic Society Award, 1997   
  • Junior Faculty Award, American Federation of Medical Research, 1999 
  • Gill Heart Institute Physician Scientist Award, University of Kentucky, Lexington Ky., 2001 
  • Election, American Society for Clinical Investigation, 2003 
  • John J. Ferchill Award for Innovation, Cleveland Clinic, 2004 
  • Nomination, Howard Hughes Medical Institute Investigator Award, 2004 
  • Vice-Chair, Gordon Research Conference on Oxygen Radicals, 2006 
  •  Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular, 2007 

Innovations & Patents

  • Patent Title: Diagnostic Methods for Asthma; U.S. Serial Number 09/253,380
  • Patent Title: Myeloperoxidase, a Risk Indicator for Cardiovascular Disease; U.S., Serial Number 10/039,753
  • Patent Title: Treating Inflammation and Associated Complications; Patent Reference Number 09531-030P01 (Pending)
  • Patent Title: Methods of Identifying Subjects at Increased Risk for Cardiovascular Disease; U.S. Serial Number 60/259,340 (Pending)
  • Patent Title: Monitoring Anti-inflammatory and Anti-oxidant Actions of Therapies; U.S. Serial Number (Pending)
  • Patent Title: Diagnostic Method for Identifying Subjects at Risk for Atherosclerosis and its Complications; U.S. Serial Number (Pending)

Memberships

  • American Society for Clinical Investigation
  • American Association for the Advancement of Science
  • American Heart Association Scientific Council for Arteriosclerosis
  • American Society for Investigative Pathology
  • American College of Cardiology

Treatment & Services

  • Cardiac Rehabilitation
  • C-Reactive Protein Testing
  • Preventive Cardiology

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 3/20/2014, Dr. Hazen has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Hazen receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • Cleveland HeartLab, Inc.
  • Esperion Therapeutics, Inc.
  • LipoScience, Inc.
  • Procter & Gamble

Royalty Payments. Dr. Hazen receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:

  • Cleveland HeartLab, Inc.
  • Esperion Therapeutics, Inc.
  • Frantz Biomarkers
  • LipoScience, Inc.
  • Siemens Healthcare Diagnostics, Inc.

Equity. Dr. Hazen owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:

  • Cleveland HeartLab, Inc.

Right to Future Distribution of Cleveland Clinic Financial Interest. Dr. Hazen may receive future financial benefits from the Cleveland Clinic for inventions or discoveries commercialized through the companies shown below:

  • Cleveland HeartLab, Inc.
  • Esperion Therapeutics, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English